Wednesday, August 20, 2014
Late on a Sunday evening in 2009, Robert Broyles, pushed a key on a computer and submitted a grant application to the Bill and Melinda Gates Foundation.
Then a professor at the University of Oklahoma College of Medicine, Broyles was advancing a novel approach to curing a devastating genetic blood disorder called sickle cell disease, which afflicts about 100,000 Americans and an estimated 50 million people worldwide.
The $100,000 grant from the Gates Foundation would allow his Sickle Cell Cure Foundation to continue pre-clinical work on a compound called EDX-17. The EDX-17 therapeutic under development was designed to reverse sickle cell disease and a related disorder called beta-thalassemia, by restoring fetal hemoglobin in adult humans who carry the sickle cell gene.
Broyles didn’t have to wait long for answer from the Gates Foundation. It was “no.”
“I sent the application in at 9 p.m. on a Sunday night and by 9 a.m. on Monday morning they had sent a message back that said they’re not interested in sickle cell,” Broyles recalled.
So he regrouped and took another approach. EDX-17 shows just as much promise in stopping malaria, a deadly disease spread worldwide by mosquitoes.
“We realized from the literature that this thing we were trying to do, which is turn on fetal hemoglobin in adult red blood cells, not only would block sickling, but also blocks the malaria parasite trying to get into this red blood cell,” Broyles said.
The World Health Organization reported 207 million malaria cases in 2012 alone.
Broyles submitted another grant application.
This time, the Gates Foundation awarded a $100,000 grant, which allowed Broyles and research partner Robert Floyd, to found a company called EpimedX LLC.
Read more of this story at NewsOK.com.